Last reviewed · How we verify
Panobinostat Nanoparticle Formulation MTX110
Panobinostat Nanoparticle Formulation MTX110 is a Small molecule drug developed by Sabine Mueller, MD, PhD. It is currently in Phase 1 development. Also known as: MTX-110, MTX110 (CN).
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Panobinostat Nanoparticle Formulation MTX110 |
|---|---|
| Also known as | MTX-110, MTX110 (CN) |
| Sponsor | Sabine Mueller, MD, PhD |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Infusion of Panobinostat (MTX110) Into the Fourth Ventricle in Children and Adults with Recurrent Medulloblastoma (EARLY_PHASE1)
- A Study of Intra-tumoral Administered MTX110 in Patients With Recurrent Glioblastoma (PHASE1)
- CED of MTX110 Newly Diagnosed Diffuse Midline Gliomas (PHASE1)
- MTX110 by Convection-Enhanced Delivery in Treating Participants With Newly-Diagnosed Diffuse Intrinsic Pontine Glioma (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Panobinostat Nanoparticle Formulation MTX110 CI brief — competitive landscape report
- Panobinostat Nanoparticle Formulation MTX110 updates RSS · CI watch RSS
- Sabine Mueller, MD, PhD portfolio CI
Frequently asked questions about Panobinostat Nanoparticle Formulation MTX110
What is Panobinostat Nanoparticle Formulation MTX110?
Who makes Panobinostat Nanoparticle Formulation MTX110?
Is Panobinostat Nanoparticle Formulation MTX110 also known as anything else?
What development phase is Panobinostat Nanoparticle Formulation MTX110 in?
Related
- Manufacturer: Sabine Mueller, MD, PhD — full pipeline
- Also known as: MTX-110, MTX110 (CN)
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing